Search results for "MESH: Time Factors"

showing 10 items of 18 documents

Molecular phylogeny of the extinct giant deer, Megaloceros giganteus.

2006

a Centre de Genetique Moleculaire et Cellulaire (CGMC), CNRS UMR 5534, Universite Claude Bernard Lyon 1, Villeurbanne, France b Laboratoire d’Anthropologie des Populations du Passe, CNRS UMR 5199 PACEA, Universite Bordeaux 1, Talence, France c UCD School of Biology and Environmental Science, UCD, BelWeld, Dublin 4, Ireland d Laboratoire d’Ecologie des Hydrosystemes Fluviaux, CNRS UMR 5023, Universite Claude Bernard Lyon 1, Villeurbanne, France e Biogeosciences-Dijon, CNRS UMR 5561, Universite de Bourgogne, Centre des Sciences de la Terre, Dijon, France f Department of Palaeontology, Royal Belgian Institute of Natural Sciences, Brussels, Belgium g Department of Biology, University College Lo…

0106 biological sciencesTime FactorsMESH: GeographyMESH: Base Sequence[SDV.BID.SPT]Life Sciences [q-bio]/Biodiversity/Systematics Phylogenetics and taxonomy01 natural sciencesMESH: FossilsMESH : BiodiversityMESH: AnimalsMESH: PhylogenyGiant deerPhylogenyComputingMilieux_MISCELLANEOUS[ SDU.STU.PG ] Sciences of the Universe [physics]/Earth Sciences/Paleontology0303 health sciencesbiologyAncient DNAGeographyEcologymtDNAFossils[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]MegalocerosMESH : GeographyClaude bernardBiodiversityMESH : Deer[ SDV.GEN.GPO ] Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE][SDU.STU.PG]Sciences of the Universe [physics]/Earth Sciences/PaleontologyMESH : Time Factors[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]MESH: Deer010603 evolutionary biologyMESH: BiodiversityQuaternary03 medical and health sciencesGeneticsAnimals14. Life underwaterMolecular BiologyEcology Evolution Behavior and Systematics030304 developmental biologyBase SequenceDeerMESH: Time FactorsMESH : Phylogenybiology.organism_classificationMESH : FossilsMESH : Base SequenceMESH : AnimalsHumanities[ SDV.BID.SPT ] Life Sciences [q-bio]/Biodiversity/Systematics Phylogenetics and taxonomy
researchProduct

Medium-size droplets of methyl ricinoleate are reduced by cell-surface activity in the gamma-decalactone production by Yarrowia lipolytica.

2000

International audience; Size of methyl ricinoleate droplets during biotransformation into gamma-decalactone by Yarrowia lipolytica was measured in both homogenized and non-homogenized media. In non-homogenized but shaken medium, droplets had an average volume surface diameter d32 of 2.5 microm whereas it was 0.7 microm in homogenized and shaken medium. But as soon as yeast cells were inoculated, both diameters became similar at about 0.7 microm and did not vary significantly until the end of the culture. The growth of Y. lipolytica in both media was very similar except for the lag phase which was lowered in homogenized medium conditions.

0106 biological sciences[SDV.BIO]Life Sciences [q-bio]/BiotechnologyTime FactorsCell01 natural sciencesApplied Microbiology and BiotechnologyLactonesBiotransformationMESH : Particle SizeYeastsMESH: Microscopy Confocal[INFO.INFO-BT]Computer Science [cs]/BiotechnologyComputingMilieux_MISCELLANEOUSBiotransformation0303 health sciencesMicroscopyMicroscopy ConfocalbiologyMESH: YeastsMESH : Lactones[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologymedicine.anatomical_structureBiochemistryConfocalSURFACE ACTIVERicinoleic Acids[ INFO.INFO-BT ] Computer Science [cs]/BiotechnologyMESH: LactonesMESH : Time Factors03 medical and health sciencesMESH : Biotransformation010608 biotechnologymedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH: Particle SizeParticle SizeMESH : Microscopy Confocal[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMethyl ricinoleateMESH: BiotransformationMESH : YeastsChromatography030306 microbiologyMESH: Time Factors[ SDV.BIO ] Life Sciences [q-bio]/BiotechnologyYarrowiabiology.organism_classificationYeastMESH: Ricinoleic AcidsCulture Media[SDV.BIO] Life Sciences [q-bio]/Biotechnology[INFO.INFO-BT] Computer Science [cs]/BiotechnologyMESH : Ricinoleic AcidsMESH: Culture MediaMESH : Culture Media
researchProduct

Effect of oxidative stress on UDP-glucuronosyltransferases in rat astrocytes.

2012

WOS:000309170300003; International audience; The present work reports data regarding effects of an induced oxidative stress on the mainly expressed isoforms of UDP-glucuronosyltransferases (UGTs) in the brain. UGT1A6 and UGT1A7 expression and enzymatic activities toward the 1-naphthol were analyzed in rat cultured astrocytes following the exposure for 48 h to redox-cycling xenobiotic compounds such as quinones and bipyridinium ions. The expression of NADPH:cytochrome P450 reductase and NAD(P)H:quinone oxidoreductase 1 (NQO1) was also investigated. Oxidative stress induced significant deleterious changes in astrocyte morphology, decreased cell viability and inhibited catalytic function of UG…

MESH : Oxidative StressMESH : RNA MessengerAntioxidantTranscription Geneticmedicine.medical_treatmentToxicologyNAD(P)H:quinone oxidoreductase 1MESH: GlucuronosyltransferaseAntioxidantsSubstrate SpecificityRats Sprague-Dawley0302 clinical medicineMESH: NADPH-Ferrihemoprotein ReductaseMESH: GlucuronidesNAD(P)H Dehydrogenase (Quinone)MESH : CatalysisMESH: AnimalsMESH : NAD(P)H Dehydrogenase (Quinone)GlucuronosyltransferaseCells Culturedchemistry.chemical_classificationMESH : Cell Survival0303 health sciencesMESH : Substrate SpecificityMESH : Animals NewbornCytochrome P450 reductaseGeneral MedicineMESH: Cell SurvivalMESH: Pyridinium CompoundsMESH : AntioxidantsMESH: Cells CulturedOxidative phosphorylationGene Expression Regulation EnzymologicMESH : QuinonesMESH : Glucuronides03 medical and health sciencesRNA MessengerCell ShapeNADPH-Ferrihemoprotein ReductaseMESH : Oxidation-ReductionMESH : Pyridinium CompoundsMESH: NaphtholsMESH : GlucuronosyltransferaseMESH: AntioxidantsMESH: CatalysischemistryOxidative stressAstrocytesReactive Oxygen Species030217 neurology & neurosurgeryMESH: Oxidation-ReductionTime Factors[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH : Reactive Oxygen SpeciesNADPH:cytochrome P450 reductasePyridinium CompoundsNaphtholsMESH: Rats Sprague-DawleyProtein oxidationmedicine.disease_causeMESH: Animals NewbornMESH: NAD(P)H Dehydrogenase (Quinone)Protein CarbonylationMESH : OxidantsMESH: OxidantsMelatoninMESH: MelatoninMESH: Oxidative StressMESH : MelatoninMESH : RatsMESH: Gene Expression Regulation EnzymologicQuinonesMESH: Reactive Oxygen SpeciesOxidantsBiochemistryMESH : Protein CarbonylationOxidation-ReductionUDP-glucuronosyltransferaseMESH : Time FactorsMESH: Protein CarbonylationMESH: RatsCell SurvivalMESH : NaphtholsBiologyCatalysisMESH: QuinonesMESH : Gene Expression Regulation EnzymologicGlucuronidesMESH : Cells CulturedmedicineAnimalsMESH: Cell Shape030304 developmental biologyMESH: RNA MessengerReactive oxygen speciesMESH: Transcription GeneticMESH: Time FactorsMESH : AstrocytesMESH : Transcription GeneticNAD(P)H Dehydrogenase (Quinone)MESH : Rats Sprague-DawleyRatsMESH: AstrocytesAnimals NewbornMESH : NADPH-Ferrihemoprotein ReductaseMESH: Substrate SpecificityMESH : AnimalsNAD+ kinaseMESH : Cell Shape[SDV.AEN]Life Sciences [q-bio]/Food and NutritionOxidative stress
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells.

2011

International audience; BACKGROUND & AIMS: Fas belongs to the family of tumor necrosis factor receptors which induce apoptosis. Many cancer cells express Fas but do not undergo Fas-mediated apoptosis. Nitric oxide reverses this resistance by increasing levels of Fas at the plasma membrane. We studied the mechanisms by which NO affects Fas function. METHODS: Colon and mammary cancer cell lines were incubated with the NO donor glyceryl trinitrate or lipid A; S-nitrosylation of Fas was monitored using the biotin switch assay. Fas constructs that contained mutations at cysteine residues that prevent S-nitrosylation were used to investigate the involvement of S-nitrosylation in Fas-mediated cell…

MESH: NitroglycerinMESH: Signal TransductionTime FactorsMESH: Membrane MicrodomainsApoptosisMESH : Fas Ligand ProteinCytoplasmic partMESH: Lipid AFas ligandMiceNitroglycerin0302 clinical medicineMESH : Protein TransportMESH : FemaleMESH: AnimalsFADDLipid raft0303 health sciencesTumorbiologyColon CancerMESH : Lipid AMESH : BiotinylationGastroenterologyFas receptorMESH: Antigens CD95Protein TransportLipid AMESH : Colonic NeoplasmsMESH : Nitric OxideMESH : Nitric Oxide Donors030220 oncology & carcinogenesisColonic NeoplasmsDeath-inducing signaling complexFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH : MutationMESH : TransfectionSignal TransductionMESH : Time FactorsMESH: Protein TransportFas Ligand ProteinMESH : Mammary Neoplasms ExperimentalMESH: MutationMESH: Cell Line TumorMESH: Mammary Neoplasms ExperimentalNitric OxideTransfectionCaspase 803 medical and health sciencesMembrane MicrodomainsCell Line TumorMESH : MiceAnimalsHumansBiotinylationNitric Oxide DonorsMESH: BiotinylationCysteinefas ReceptorMESH: MiceMESH : Protein Processing Post-Translational030304 developmental biologyMESH : Signal TransductionMESH: Colonic NeoplasmsMESH : CysteineMESH: HumansHepatologyMESH : Cell Line TumorMESH: ApoptosisMESH: TransfectionMESH : HumansMESH: Time FactorsMammary Neoplasms Experimental[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: CysteineMESH: Nitric Oxide DonorsMolecular biologySignalingMESH: Fas Ligand ProteinMESH : NitroglycerinApoptosisLocalizationMESH: Nitric OxideMESH: Protein Processing Post-TranslationalMutationbiology.proteinMESH : Membrane MicrodomainsMESH : AnimalsMESH : Antigens CD95Protein Processing Post-TranslationalMESH: FemaleMESH : Apoptosis
researchProduct

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colore…

2016

IF 2.415; International audience; The haemoglobin concentration measured by faecal immunochemical tests (FIT) may be decreased in cases of delayed sample return or high temperature. It is an issue of great importance. The aim of this study was to investigate the effects of sample return time and of season on the performance of an FIT (FOB-Gold) with a new buffer. The study included 20 371 participants involved in the French organized colorectal cancer (CRC) screening programme. The probability of a positive screening test, detection rates and positive predictive values for CRC and advanced adenoma were analysed according to sample return time and season of screening. A sample of positive FI…

MaleCancer ResearchMultivariate analysisTime FactorsEpidemiologyColorectal cancerMESH: Reagent Kits DiagnosticMESH : AgedMESH : HemoglobinsMESH : Early Detection of Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerReturn timeScreening programmeImmunoenzyme TechniquesHemoglobinsMESH : Specimen HandlingMESH : FemaleMESH : Neoplasm StagingMESH : Reagent Kits DiagnosticMESH : TemperatureEarly Detection of CancerMESH: AgedMESH: Middle AgedMESH : PrognosisTemperatureMESH: Follow-Up StudiesMESH: Neoplasm StagingMiddle AgedPrognosisPredictive valueMESH: TemperatureMESH: HemoglobinsMESH : Occult BloodOncologyColorectal cancer screeningOccult BloodFemaleSeasonsMESH : Colorectal NeoplasmsColorectal NeoplasmsMESH : Time FactorsAdenomamedicine.medical_specialtySample (material)MESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerMESH: PrognosisSpecimen HandlingAnimal scienceMESH : Immunoenzyme TechniquesmedicineHumansMESH: Early Detection of CancerMESH : Middle AgedMESH: Specimen HandlingMESH: Immunoenzyme TechniquesAgedNeoplasm StagingMESH: AdenomaMESH: HumansMESH : Seasonsbusiness.industryMESH: Time FactorsMESH : HumansPublic Health Environmental and Occupational HealthMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleSurgeryMESH : AdenomaReagent Kits DiagnosticFaecal occult blood testbusinessMESH: Occult BloodMESH: FemaleMESH: SeasonsMESH: Colorectal NeoplasmsFollow-Up Studies
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Medical pre-hospital management reduces mortality in severe blunt trauma: a prospective epidemiological study

2011

International audience; INTRODUCTION: Severe blunt trauma is a leading cause of premature death and handicap. However, the benefit for the patient of pre-hospital management by emergency physicians remains controversial because it may delay admission to hospital. This study aimed to compare the impact of medical pre-hospital management performed by SMUR (Service Mobile d'Urgences et de Réanimation) with non-medical pre-hospital management provided by fire brigades (non-SMUR) on 30-day mortality. METHODS: The FIRST (French Intensive care Recorded in Severe Trauma) study is a multicenter cohort study on consecutive patients with severe blunt trauma requiring admission to university hospital i…

MaleEmergency Medical ServicesTime FactorsMESH : AgedMESH : Prospective StudiesPoison controlCritical Care and Intensive Care Medicine0302 clinical medicineInjury Severity ScorePatient AdmissionEmergency medical services[ SHS.INFO ] Humanities and Social Sciences/Library and information sciences030212 general & internal medicineHospital MortalityProspective StudiesProspective cohort studyMESH: Treatment OutcomeMESH: AgedMESH: Middle AgedMortality rate[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMESH : Patient AdmissionMESH : AdultMiddle Aged3. Good healthMESH : Wounds and InjuriesIntensive Care UnitsTreatment OutcomeBlunt traumaMESH: Young AdultBlunt traumaMESH: Emergency Medical ServicesInjury Severity ScoreMESH : Injury Severity ScoreFranceMESH: FirefightersMESH : Intensive Care UnitsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyAdolescentMESH : Male[SHS.INFO]Humanities and Social Sciences/Library and information sciencesMESH: Injury Severity ScoreMESH : Young AdultMESH : Treatment Outcome[SHS.INFO] Humanities and Social Sciences/Library and information sciencesMESH : Hospital Mortality03 medical and health sciencesYoung AdultIntensive careMESH : AdolescentmedicineHumansMESH : Emergency Medical ServicesMESH : Middle AgedMESH: Hospital MortalityIntensive care medicineMESH : FranceAgedMESH: AdolescentMESH: Humansbusiness.industryMESH: Patient AdmissionResearchMESH : HumansMESH: Time Factors030208 emergency & critical care medicineMESH: AdultMESH: MaleMESH: Prospective StudiesMESH: France[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesFirefightersEmergency medicineWounds and InjuriesMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH : FirefightersbusinessCritical Care
researchProduct

Acute in vivo administration of a fish oil-containing emulsion improves post-ischemic cardiac function in n-3-depleted rats

2006

International audience; A novel i.v. lipid preparation (MCT:FO) containing 80% medium chain-triacylglycerols and 20% fish oil was recently developed to rapidly replenish cell membrane phospholipids with omega 3 (n-3) polyunsaturated fatty acids (PUFA). In regard of this property, we investigated the effect of a single i.v. administration of MCT:FO on the recovery of cardiac function after ischemia in control and n-3-depleted rats. Results were compared with those obtained either with a control preparation, where FO was replaced by triolein (MCT:OO), or with saline. Saline (1 ml) or lipid preparation (also 1 ml) was injected as a bolus via the left saphenous vein. After 60 min the heart was …

MaleFat EmulsionsTime Factorsmedicine.medical_treatmentMyocardial IschemiaWistar030204 cardiovascular system & hematologyPharmacologyLIPID PREPARATIONchemistry.chemical_compound0302 clinical medicineBolus (medicine)MESH: Fatty Acids Omega-3Heart Rate[SDV.IDA]Life Sciences [q-bio]/Food engineeringMedicineMESH: AnimalsMESH: Oxygen ConsumptionTrioleinMESH: Heart RateSalineOMEGA3-DEFICIENCYOmega-3chemistry.chemical_classification0303 health sciencesFatty AcidsHeartGeneral Medicine[SDV.IDA] Life Sciences [q-bio]/Food engineeringFish oilMESH: Myocardial Reperfusion Injury3. Good healthLactatesMESH: Myocardial IschemiaIntravenousPolyunsaturated fatty acidCardiac function curveFat Emulsions Intravenousmedicine.medical_specialtyMESH: Rats[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process EngineeringACIDE GRAS POLYINSATURE OMEGA3IschemiaMESH: Fish OilsMyocardial Reperfusion InjuryMESH: Coronary CirculationMESH: Lactates03 medical and health sciencesISCHEMIA-REPERFUSIONFish OilsOxygen ConsumptionIn vivoCoronary CirculationMESH: Analysis of VarianceFatty Acids Omega-3[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyGeneticsAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringRats WistarLANGENDORFF030304 developmental biologyAnalysis of Variancebusiness.industryBody WeightMESH: Time FactorsMESH: Rats Wistarmedicine.diseaseMESH: MaleRatsMESH: Body WeightMESH: Fat Emulsions IntravenousSurgeryMESH: Heartchemistrybusiness
researchProduct

Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study.

2016

IF 2.271; International audience; Background. - Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality.Objective. - To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI).Methods. - Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model.Results. - At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were youn…

MaleMESH: Chi-Square Distributionmedicine.medical_treatmentMESH : Acute Coronary SyndromeMyocardial InfarctionMESH : AgedMESH : Prospective StudiesCardiac rehabilitationMESH: Risk Assessment0302 clinical medicineMyocardial infarctionProspective StudiesReferral and ConsultationMESH: Treatment OutcomeRehabilitationMESH: Middle AgedGeneral MedicineMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionMESH : Patient DischargeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute myocardial infarctionMortalitéRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedAcute Coronary SyndromeMESH: Kaplan-Meier EstimateAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionProportional hazards modelMESH: Patient DischargeMESH : HumansPatient survivalMESH : Follow-Up Studiesmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Acute Coronary SyndromeST-segment elevation myocardial infarctionMESH: FemaleTime FactorsMESH: RegistriesKaplan-Meier Estimate030204 cardiovascular system & hematologyMESH : Referral and ConsultationMESH: Proportional Hazards ModelsOlder patientsRisk FactorsMESH: Risk FactorsMESH : Female030212 general & internal medicineRegistriesMESH : Risk AssessmentMESH: AgedEjection fractionNon–ST-segment elevation myocardial infarctionMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsPatient DischargeTreatment OutcomeFemaleFranceMESH : Time FactorsMESH : MaleMESH : Treatment OutcomeMESH: Multivariate AnalysisMESH : Kaplan-Meier EstimateMESH: Referral and ConsultationInternal medicineInfarctus du myocarde sans sus-décalage du segment STmedicineIn patientcardiovascular diseasesMedical prescriptionMortalityRéadaptation cardiaqueMESH : FranceProportional Hazards Modelsbusiness.industryInfarctus du myocarde avec sus-décalage du segment STMESH: Time FactorsMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceInfarctus du myocarde aiguMultivariate AnalysisMESH : Myocardial InfarctionbusinessMESH : RegistriesFollow-Up Studies
researchProduct